
CORRIGENDUM

Metabolic targets for cancer therapy

Lorenzo Galluzzi, Oliver Kepp, Matthew G. Vander Heiden and Guido Kroemer

Nature Reviews Drug Discovery 12, 829–846 (2013)

There were some inaccuracies in the following sentence on p839 of the article: "Along similar lines, the pharmacological or genetic inhibition of phosphoglycerate mutase 1 (PGAM1) reduces tumour growth *in vitro* and *in vivo*, perhaps owing (at least in part) to the G6PD-inhibitory effects of 3-phosphoglycerate²²². That said, genetic defects that have an impact on the enzymatic activity of G6PD are common among individuals living in geographical areas with a history of endemic malaria²²³."

The correct sentence is as follows: "Along similar lines, the pharmacological or genetic inhibition of phosphoglycerate mutase 1 (PGAM1) reduces tumour growth *in vitro* and *in vivo*, perhaps owing (at least in part) to the PPP-inhibitory effects of 3-phosphoglycerate²²². That said, genetic defects that have an impact on the enzymatic activity of G6PD (and hence inhibit the PPP) are common among individuals living in geographical areas with a history of endemic malaria²²³."

This has now been corrected in the online version of the article.